PE Guidelines logo
Pharmacoeconomic Guidelines Around The World

Country/Region: Israel

Submission Guidelines
Guidelines for the Submission of a Request to Include a Pharmaceutical Product in the National List of Health Services - Appendix D: Instructions for Performing an Economic Assessment (2010)
PDF in English (page 14-21)

Submission Guidelines Source:
State of Israel Ministry of Health – Pharmaceutical Administration
http://www.health.gov.il/english/

Additional Information:
Guidelines for the Submission of a Request to Include a Pharmaceutical Product in the National List of Health Services – Appendix B: Instructions for Performing an Economic Assessment (2002)
PDF in English (page 24-28)

Last Webpage Update: Wednesday, April 20, 2011

Submission Guidelines Key Features:

Key Features:  
Title and year of the documentGuidelines for the Submission of a Request to Include a Pharmaceutical Product in the National List of Health Services - Appendix D: Instructions for Performing an Economic Assessment (2010) 
Affiliation of authorsPharmacoepidemiology and Pharmacoeconomics Department, Pharmaceutical Administration of the Ministry of Health 
Purpose of the documentSubmission for a listing of new drug products 
Standard reporting format includedYes 
DisclosureNot stated 
Target audience of funding/ author's interestsPharmaceutical companies, Pharmacoepidemiology and Pharmacoeconomics Department, Pharmaceutical Administration of the Ministry of Health 
PerspectiveSick Funds of the National Health Insurance 
IndicationYes 
Target populationYes 
Subgroup analysisNot stated 
Choice of comparatorNot specific, all alternatives 
Time horizonNot stated 
Assumptions requiredNot stated 
Preferred analytical techniqueCost effectiveness evaluation 
Costs to be includedTreatment costs, resources to support therapy and treat side effects and treatment failures 
Source of costsMinistry of Health’s ambulatory services’ price 
ModelingYes, requires details 
Systematic review of evidencesYes 
Preference for effectiveness over efficacyNot stated 
Preferred outcome measureFinal outcomes 
Preferred method to derive utilityNot stated 
Equity issues statedNot stated 
Discounting costsNot stated 
Discounting outcomesNot stated 
Sensitivity analysis-parameters and rangeImpact of the uncertainty of the different data on the strength of the assessments. 
Sensitivity analysis-methodsNot stated 
Presenting resultsNot stated 
Incremental analysisNot stated 
Total costs vs effectiveness (cost/effectiveness ratio)Not stated 
Portability of results (Generalizability)Yes 
Financial impact analysisYes, first three years following the inclusion. 
Mandatory or recommended or voluntary 

Country Selection Page | PE Guidelines Index Page